NOVO — November 2023
-
Man kan læse hele nyheden her. Senere får vi nok selve præsentationen at se https://ml-eu.globenewswire.com/Resource/Download/204ffb89-dd0f-46f1-918b-c6681355f852
-
Præsentationen (den første)
starter 1630 DK time -
Jep og DET er mega interessant. Det er stadig et stort HVIS. Men hvis det er mere molecule relateret end blot glp1 relateret. puha
-
Vi kommer tæt på 300 mia i oms næste år. med yderligere 35-40% ebit vækst. Det bliver nogle gode udbytte dage
-
MF det er de hvis ikke helt klar til at konkludere endnu. Men der er nogle indikationer der åbenbart peger den vej, jvf stor artikel i Børsen
-
Det begynder at ligne en realistisk mulighed for at runde 1000 igen inden udgangen af 24
-
Sørme om ikke der også lige er blevet publiceret 2 nye artikler i The New England Journal of Medicine
-
-
-
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy
) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicin https://www.proinvestor.com/boards/116672 -
MF det tror jeg ikke. Det ligner lidt der skal en del nye forsøg til for at kunne fortage en sådan konklusion. Herunder H2H med andre stoffer
-
A key question about the initial results, though, remained not fully answered: Is the heart benefit from Wegovy attributable to how much weight people lose while using the medicine? Or is it because Wegovy has other effects as well?
-
“It remains unclear to what degree the trial findings were dependent on weight loss, concomitant reductions in risk factors, or other salutary mechanisms of GLP-1 receptor agonism,”
-
“I think most of us believe that some of this is weight loss, but I think that that oversimplifies a very complex molecule, a complex receptor on multiple tissues, and I don’t think it’s as a simple as that,” he said. “That’s part of the reason why I don’t think weight loss itself is the surrogate; we have to look at the mechanism of the weight loss.”
-
He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.
“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.
In the U.S., there are about 6.6 million people like those tested in the study, experts said.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind